ZA200104283B - Method of treating sexual disturbances. - Google Patents
Method of treating sexual disturbances. Download PDFInfo
- Publication number
- ZA200104283B ZA200104283B ZA200104283A ZA200104283A ZA200104283B ZA 200104283 B ZA200104283 B ZA 200104283B ZA 200104283 A ZA200104283 A ZA 200104283A ZA 200104283 A ZA200104283 A ZA 200104283A ZA 200104283 B ZA200104283 B ZA 200104283B
- Authority
- ZA
- South Africa
- Prior art keywords
- substance
- composition
- sexual
- medicament
- compound according
- Prior art date
Links
- 230000001568 sexual effect Effects 0.000 title claims description 128
- 238000000034 method Methods 0.000 title claims description 58
- 150000001875 compounds Chemical class 0.000 claims description 124
- 239000003814 drug Substances 0.000 claims description 77
- 239000000203 mixture Substances 0.000 claims description 74
- 239000000126 substance Substances 0.000 claims description 53
- 241000282414 Homo sapiens Species 0.000 claims description 50
- 229940079593 drug Drugs 0.000 claims description 35
- 230000013011 mating Effects 0.000 claims description 29
- BNRNXUUZRGQAQC-UHFFFAOYSA-N sildenafil Chemical compound CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 BNRNXUUZRGQAQC-UHFFFAOYSA-N 0.000 claims description 28
- 150000003839 salts Chemical class 0.000 claims description 26
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 25
- 239000003795 chemical substances by application Substances 0.000 claims description 18
- LISFMEBWQUVKPJ-UHFFFAOYSA-N carbostyril Natural products C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 17
- 208000010228 Erectile Dysfunction Diseases 0.000 claims description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 230000000694 effects Effects 0.000 claims description 15
- 230000033904 relaxation of vascular smooth muscle Effects 0.000 claims description 15
- 208000006262 Psychological Sexual Dysfunctions Diseases 0.000 claims description 14
- 206010015037 epilepsy Diseases 0.000 claims description 13
- 230000035946 sexual desire Effects 0.000 claims description 13
- 206010024419 Libido decreased Diseases 0.000 claims description 11
- 108010003205 Vasoactive Intestinal Peptide Proteins 0.000 claims description 11
- 102400000015 Vasoactive intestinal peptide Human genes 0.000 claims description 11
- 208000017020 hypoactive sexual desire disease Diseases 0.000 claims description 11
- GMVPRGQOIOIIMI-DWKJAMRDSA-N prostaglandin E1 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(O)=O GMVPRGQOIOIIMI-DWKJAMRDSA-N 0.000 claims description 11
- 229960003310 sildenafil Drugs 0.000 claims description 11
- 206010058359 Hypogonadism Diseases 0.000 claims description 10
- XQYZDYMELSJDRZ-UHFFFAOYSA-N papaverine Chemical compound C1=C(OC)C(OC)=CC=C1CC1=NC=CC2=CC(OC)=C(OC)C=C12 XQYZDYMELSJDRZ-UHFFFAOYSA-N 0.000 claims description 10
- QJOMEJDBLGGZNA-MRVPVSSYSA-N (5r)-5-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1h)-thione Chemical compound C([C@H](C1)NC)C2=CC=CC3=C2N1C(=S)N3 QJOMEJDBLGGZNA-MRVPVSSYSA-N 0.000 claims description 9
- GMVPRGQOIOIIMI-UHFFFAOYSA-N (8R,11R,12R,13E,15S)-11,15-Dihydroxy-9-oxo-13-prostenoic acid Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CCCCCCC(O)=O GMVPRGQOIOIIMI-UHFFFAOYSA-N 0.000 claims description 9
- 229960000711 alprostadil Drugs 0.000 claims description 9
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 9
- 208000014840 female orgasmic disease Diseases 0.000 claims description 9
- 238000009802 hysterectomy Methods 0.000 claims description 9
- 201000004197 inhibited female orgasm Diseases 0.000 claims description 9
- 208000009798 Craniopharyngioma Diseases 0.000 claims description 8
- 208000030431 Male orgasmic disease Diseases 0.000 claims description 8
- 201000000068 inhibited male orgasm Diseases 0.000 claims description 8
- 208000015421 male orgasm disease Diseases 0.000 claims description 8
- 238000009806 oophorectomy Methods 0.000 claims description 8
- 241000283086 Equidae Species 0.000 claims description 7
- 208000021663 Female sexual arousal disease Diseases 0.000 claims description 7
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 claims description 7
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 7
- -1 phetolamine Chemical compound 0.000 claims description 7
- 229960000317 yohimbine Drugs 0.000 claims description 7
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 claims description 7
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 claims description 7
- 241000124008 Mammalia Species 0.000 claims description 6
- 239000000674 adrenergic antagonist Substances 0.000 claims description 6
- 230000007812 deficiency Effects 0.000 claims description 6
- MRBDMNSDAVCSSF-UHFFFAOYSA-N phentolamine Chemical compound C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 MRBDMNSDAVCSSF-UHFFFAOYSA-N 0.000 claims description 6
- 229960001999 phentolamine Drugs 0.000 claims description 6
- 229930008281 A03AD01 - Papaverine Natural products 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 229960001789 papaverine Drugs 0.000 claims description 5
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 claims description 5
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 4
- 239000002840 nitric oxide donor Substances 0.000 claims description 4
- 239000002571 phosphodiesterase inhibitor Substances 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 3
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 claims description 3
- 241000282693 Cercopithecidae Species 0.000 claims description 3
- 241000282326 Felis catus Species 0.000 claims description 3
- 241001272567 Hominoidea Species 0.000 claims description 3
- 241000699660 Mus musculus Species 0.000 claims description 3
- 206010031127 Orthostatic hypotension Diseases 0.000 claims description 3
- 208000025174 PANDAS Diseases 0.000 claims description 3
- 208000021155 Paediatric autoimmune neuropsychiatric disorders associated with streptococcal infection Diseases 0.000 claims description 3
- 240000004718 Panda Species 0.000 claims description 3
- 235000016496 Panda oleosa Nutrition 0.000 claims description 3
- 241000282320 Panthera leo Species 0.000 claims description 3
- 241000282376 Panthera tigris Species 0.000 claims description 3
- 241001494479 Pecora Species 0.000 claims description 3
- 241000283080 Proboscidea <mammal> Species 0.000 claims description 3
- 241000282898 Sus scrofa Species 0.000 claims description 3
- 241000282458 Ursus sp. Species 0.000 claims description 3
- 229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 claims description 3
- 230000001856 erectile effect Effects 0.000 claims description 3
- 229960002006 linsidomine Drugs 0.000 claims description 3
- FKDHHVKWGRFRTG-UHFFFAOYSA-N linsidomine Chemical compound [N-]1OC(=N)C=[N+]1N1CCOCC1 FKDHHVKWGRFRTG-UHFFFAOYSA-N 0.000 claims description 3
- 229960003574 milrinone Drugs 0.000 claims description 3
- PZRHRDRVRGEVNW-UHFFFAOYSA-N milrinone Chemical compound N1C(=O)C(C#N)=CC(C=2C=CN=CC=2)=C1C PZRHRDRVRGEVNW-UHFFFAOYSA-N 0.000 claims description 3
- 239000002570 phosphodiesterase III inhibitor Substances 0.000 claims description 3
- 239000002590 phosphodiesterase V inhibitor Substances 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 239000000018 receptor agonist Substances 0.000 claims description 3
- 229940044601 receptor agonist Drugs 0.000 claims description 3
- WOXKDUGGOYFFRN-IIBYNOLFSA-N tadalafil Chemical compound C1=C2OCOC2=CC([C@@H]2C3=C(C4=CC=CC=C4N3)C[C@H]3N2C(=O)CN(C3=O)C)=C1 WOXKDUGGOYFFRN-IIBYNOLFSA-N 0.000 claims description 3
- 238000011830 transgenic mouse model Methods 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 2
- 229940049920 malate Drugs 0.000 claims 3
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 3
- 208000012201 sexual and gender identity disease Diseases 0.000 claims 2
- 208000015891 sexual disease Diseases 0.000 claims 2
- 206010011953 Decreased activity Diseases 0.000 claims 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
- 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 claims 1
- IRFHMTUHTBSEBK-QGZVFWFLSA-N tert-butyl n-[(2s)-2-(2,5-difluorophenyl)-3-quinolin-3-ylpropyl]carbamate Chemical compound C1([C@H](CC=2C=C3C=CC=CC3=NC=2)CNC(=O)OC(C)(C)C)=CC(F)=CC=C1F IRFHMTUHTBSEBK-QGZVFWFLSA-N 0.000 claims 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 15
- 241000282412 Homo Species 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 201000010099 disease Diseases 0.000 description 14
- 229910052736 halogen Inorganic materials 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 229910052799 carbon Inorganic materials 0.000 description 12
- 201000001881 impotence Diseases 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 238000007429 general method Methods 0.000 description 8
- 125000000217 alkyl group Chemical group 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 7
- 239000002002 slurry Substances 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000013078 crystal Substances 0.000 description 6
- 230000001976 improved effect Effects 0.000 description 6
- 239000007926 intracavernous injection Substances 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- 239000000820 nonprescription drug Substances 0.000 description 6
- 210000003899 penis Anatomy 0.000 description 6
- 239000000955 prescription drug Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 208000020016 psychiatric disease Diseases 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 125000003545 alkoxy group Chemical group 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 230000036299 sexual function Effects 0.000 description 5
- 239000007787 solid Substances 0.000 description 5
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 4
- 206010047791 Vulvovaginal dryness Diseases 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 229960002009 naproxen Drugs 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000035515 penetration Effects 0.000 description 4
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- QJOMEJDBLGGZNA-UHFFFAOYSA-N C1C(NC)CC2=CC=CC3=C2N1C(=S)N3 Chemical compound C1C(NC)CC2=CC=CC3=C2N1C(=S)N3 QJOMEJDBLGGZNA-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 3
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 description 3
- FFGPTBGBLSHEPO-UHFFFAOYSA-N carbamazepine Chemical compound C1=CC2=CC=CC=C2N(C(=O)N)C2=CC=CC=C21 FFGPTBGBLSHEPO-UHFFFAOYSA-N 0.000 description 3
- 229960000623 carbamazepine Drugs 0.000 description 3
- 238000002425 crystallisation Methods 0.000 description 3
- 230000008025 crystallization Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 230000003292 diminished effect Effects 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000007915 intraurethral administration Methods 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940094720 viagra Drugs 0.000 description 3
- CMWTZPSULFXXJA-SECBINFHSA-N (2R)-2-(6-methoxy-2-naphthalenyl)propanoic acid Chemical compound C1=C([C@@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-SECBINFHSA-N 0.000 description 2
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical compound CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 102000034755 Sex Hormone-Binding Globulin Human genes 0.000 description 2
- 108010089417 Sex Hormone-Binding Globulin Proteins 0.000 description 2
- 201000001880 Sexual dysfunction Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000004183 alkoxy alkyl group Chemical group 0.000 description 2
- 229960004046 apomorphine Drugs 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 210000003029 clitoris Anatomy 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000004550 quinolin-6-yl group Chemical group N1=CC=CC2=CC(=CC=C12)* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 230000035941 sexual motivation Effects 0.000 description 2
- 230000035936 sexual power Effects 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 229960003604 testosterone Drugs 0.000 description 2
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 229940124549 vasodilator Drugs 0.000 description 2
- 239000003071 vasodilator agent Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- QUOJSDRGEXEEEQ-DDWIOCJRSA-N (5r)-5-(methylamino)-5,6-dihydro-4h-imidazo[4,5,1-ij]quinoline-2(1h)-thione malate Chemical compound OC(=O)C(O)CC(O)=O.C([C@H](C1)NC)C2=CC=CC3=C2N1C(=S)N3 QUOJSDRGEXEEEQ-DDWIOCJRSA-N 0.000 description 1
- CXBDYQVECUFKRK-UHFFFAOYSA-N 1-methoxybutane Chemical compound CCCCOC CXBDYQVECUFKRK-UHFFFAOYSA-N 0.000 description 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 description 1
- OGIYDFVHFQEFKQ-UHFFFAOYSA-N 3-[n-(4,5-dihydro-1h-imidazol-2-ylmethyl)-4-methylanilino]phenol;methanesulfonic acid Chemical compound CS(O)(=O)=O.C1=CC(C)=CC=C1N(C=1C=C(O)C=CC=1)CC1=NCCN1 OGIYDFVHFQEFKQ-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 108060003345 Adrenergic Receptor Proteins 0.000 description 1
- 102000017910 Adrenergic receptor Human genes 0.000 description 1
- 241000282452 Ailuropoda melanoleuca Species 0.000 description 1
- 206010002942 Apathy Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- FIPWRIJSWJWJAI-UHFFFAOYSA-N Butyl carbitol 6-propylpiperonyl ether Chemical compound C1=C(CCC)C(COCCOCCOCCCC)=CC2=C1OCO2 FIPWRIJSWJWJAI-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 101150065749 Churc1 gene Proteins 0.000 description 1
- 208000034308 Grand mal convulsion Diseases 0.000 description 1
- 206010066364 Hypersexuality Diseases 0.000 description 1
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 description 1
- 206010034010 Parkinsonism Diseases 0.000 description 1
- 229940099471 Phosphodiesterase inhibitor Drugs 0.000 description 1
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 102000008866 Prostaglandin E receptors Human genes 0.000 description 1
- 108010088540 Prostaglandin E receptors Proteins 0.000 description 1
- 102100038239 Protein Churchill Human genes 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000000304 alkynyl group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000037007 arousal Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- YDVJBLJCSLVMSY-UHFFFAOYSA-N carbamoyl cyanide Chemical compound NC(=O)C#N YDVJBLJCSLVMSY-UHFFFAOYSA-N 0.000 description 1
- 229940015688 caverject Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- VRLDVERQJMEPIF-UHFFFAOYSA-N dbdmh Chemical compound CC1(C)N(Br)C(=O)N(Br)C1=O VRLDVERQJMEPIF-UHFFFAOYSA-N 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000020979 dietary recommendations Nutrition 0.000 description 1
- MHUWZNTUIIFHAS-CLFAGFIQSA-N dioleoyl phosphatidic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(O)=O)OC(=O)CCCCCCC\C=C/CCCCCCCC MHUWZNTUIIFHAS-CLFAGFIQSA-N 0.000 description 1
- 230000009429 distress Effects 0.000 description 1
- 238000009552 doppler ultrasonography Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000005461 lubrication Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 description 1
- 229940028444 muse Drugs 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229960005235 piperonyl butoxide Drugs 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108091006082 receptor inhibitors Proteins 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000009329 sexual behaviour Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 210000003905 vulva Anatomy 0.000 description 1
Description
METHOD OF TREATING SEXUAL DISTURBANCES
1. Field of the Invention
The present invention is a method of treating sexual disturbances using the ~ compounds of US Patent 5,273,975. 2. Description of the Related Art
There are a number of diseases/conditions which directly affect the sexual lives of humans and animals. These include orgasmic disorders, lack of interest in sex and erectile dysfunction in males. In addition there are a number of diseases/conditions which indirectly affect the sexual lives of humans. There are a few pharmaceutical agents to treat this diseases/conditions and others in clinical development.
US Patent 5,273,975 discloses that the compounds (A) of the present invention are ] useful to stimulate sexual activity and to alleviate impotence. The useful dosage range disclosed in US Patent 5,273,975 is “at least 10 mg up to about 1200 mg per day”. The operable dosage range in the present invention is considerably lower. The compounds of
Co US Patent 5,273,975 have been used in clinical trials to prove their usefulness in treating
Parkinson's disease at a dose of 30 mg/person. Compounds (A) of the present invention are ’ used at a dose of less than 8 mg in treating the sexual disturbances of the present invention.
US Patent 5,273,975 generically discloses compounds where the variable substituent “A” can be either a carbonyl group (-CO-) or a thiocarbonyl (-CS-).
US Patent 5,250,534 discloses sildenafil (VIAGRA®). The compounds (A) of the present invention are quite different chemically than sildenafil. International Publication
W094/282902 discloses the use of sildenafil for treating male impotence.
US Patent 4,127,118 discloses the intracavernosal injection of a vasodilator for enhancing an erection of the penis. PGE] is a vasodilator and is sold as CAVERJECT® to treat male erectile dysfunction. The compounds (A) of the present invention are not prostaglandins and are not injected into the penis.
International Journal of Impotence Research, 10 (Supplement 3), August 1998,
Abstracts #417 and 419 disclose that apomorphine, which is available in a number of countries to treat Parkinson’s Disease, is in late-stage development as a sublingual formulation for treating male erectile dysfunction. The compounds (A) used in the present invention are not apomorphine analogs. US Patent 5,770,606 discloses sublingual use of apomorphine for treating erectile dysfunction.
US Patent 5,541,211 discloses that yohimbine can be used to treat erectile dysfunction. The compound? of formula (A) are quite different chemically as compared to yohimbine.
US Patent 4,801,587 discloses that phentolamine (VASOMAX®) which is available in a number of countries for treating hypertension is also useful for treating erectile dysfunction. The compounds of formula (A) are quite different chemically as compared to phentolamine. In addition, the compounds of formula (A) are not applied either topically to the penis nor intra-urethrally.
US Patent 5,773,020 discloses that intraurethral PGE1 (MUSE) is useful for treating erectile dysfunction. Compounds (A) are not prostaglandins and are not administered intraurethrally.
Brain Research, 55, 383-389 (1973) reports on the sexually stimulating effect of L-
DOPA given to male rats and conjuctures that it may be the reason that hypersexuality occasionally is seen in patients with Parkinson’s syndrome during L-DOPA treatment.
Disclosed is a method of treating sexual disturbances in a human who is in need of such © treatment which comprises administering a sexually therapeutically effective amount of a compound of the formula (A) ) 5 x 1 = (Bn where
Ry, R; and R; are the same or different and are: -H, C,-Cg alkyl, C3-Cs alkenyl, Cs-
Cs alkynyl, C3-Cs cycloalkyl, C4-Cio cycloalkyl, phenyl substituted C;-Cs alkyl, -NR1R where R; and R; are cyclized with the attached nitrogen atom to produce pyrrolidiyl, piperidinyl, morphoninyl, 4-methyl piperazinyl or imidazolyl;
X is: -H, C,-Cs alkyl, -F, -Cl, -Br, -I, -OH, C,-Cs alkoxy, cyano, carboxamide, carboxyl, (C;-Cs alkoxy)carbonyl;
A is: CH, CH,, CH-(halogen) where halogen is -F, -Cl, -Br, -I, CHCHa,, C=0, C=S§,
C-SCH;3, C=NH, C-NH,, C-NHCHj3;, C-NHCOOCH;, C-NHCN, SO», N;
B is: CH,, CH, CH-(halogen) where halogen is as defined above, C=0, N, NH,
N-CH;,
D is: CH, CH, CH-(halogen) where halogen is as defined above, C=0, O, N, NH,
N-CH;; and n is 0 or 1, and where “ is a single or double bond, with the provisos: (1) that when n is 0, and ”
A is CH, CH-(halogen) where halogen is as defined above, CHCHj3, C=0,
C=S, C=NH, SO,;; then _D is CH;, CH-(halogen) where halogen is as defined above, C=O, O, NH, N-
CHj; (2) that when n is 0, and
A is CH, C-SCH;, C-NH;, C-NHCHj;, C-NHCOOCH;, C-NHCN, N; then
Dis CH, N, (3) that when n is 1, and
A is CH,, CH-(halogen) where halogen is as defined above, CHCHj3, C=0,
C=S, C=NH, SO;; and :
B is CH,, CH-(halogen) where halogen is as defined above, C=0, NH, N-
CH3; then
D is CH,, C=0, O, NH, N-CHj3, (4) that when n is 1, and
A is CH, C-SCHj3, C-NH,, C-NHCH3, C-NHCOOCH3;, C-NHCN, N; and
B is CH, N; then
D is CH,, C=0, O, NH, N-CH3, (5) that when nis 1, and
A is CH;, CHCH;, C=0, C=S, C=NH, SO, and
Bis CH, N; then
D is CH, N; and pharmaceutically acceptable salts thereof to the human.
Also disclosed is a method of inducing mating a non-human mammal which comprises administering a sexually mating amount of a compound of the formula (A) and pharmaceutically acceptable salts thereof.
Further disclosed is a method of treating a sexual deficiency state in a human who has epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy which comprises administering a sexually therapeutically effective amount of a compound of the formula (A) and pharmaceutically acceptable salts thereof.
Additionally disclosed is a method of increasing sexual desire, interest or performance in a human whb is desirous thereof which comprises administering a sexually useful effective amount of a compound of the formula (A) and pharmaceutically acceptable salts thereof. -
Disclosed is (SR)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline- 2(1H)-thione and pharmaceutically acceptable salts thereof.
The present invention includes four separate methods of treating sexual problems.
First, it is a method of treating sexual disturbances in a human who is in need of such treatment which comprises administering a sexually therapeutic amount of a compound of the formula (A) and its pharmaceutically acceptable salts. Second, it includes a method of inducing mating a non-human mammal which comprises administering a sexually mating amount of a compound of the formula (A) and pharmaceutically acceptable salts thereof.
Thirdly, it includes a method of treating a sexual deficiency state in a human who has a disease/condition the primary pathology of which does not relate to sexual disfunction, but indirectly produces reduced sexual functioning. The diseases/conditions which can produce = this type of sexual disfunction include epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy. Fourthly, there are i individuals who do not appear to have any sexual disturbance or disease/condition which will produced an adverse effect on their sexual lives, but none the less wish to increase their sexual desire, interest or sexual performance and who will benefit by use of the compounds of formula (A).
The compounds of formula (A), and pharmaceutically acceptable salts, which are useful in the method of treatment of the present invention are known, see US Patent 5,273,975. It is preferred that the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH3-(CH,),-COOH where n is 0 thru 4, HOOC-(CH;)n-COOH where n is as defined above. It is preferred that the compound of formula (A) have n be 0, A be C=0 and D be NH. It is more preferred that the compound of formula (A) be either (5R)-(methylamino)-5,6-dihydro-4H-imidazo(4,5,1- ijJquinolin-2(1H)-one or (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ij]quinoline- 2(1H)-thione. It is more preferred that the compound of formula (A) be (5R)-(methylamino)-5,6- dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1).
: A preferred process to produce the preferred compounds within the scope of the compounds of formula (A) 1s set forth in PREPARATION 1 and the numerical EXAMPLES as well as CHART A.
Non-human mammals include commercial animals (horses, cattle, swine, sheep and transgenic mice) and zoo animals (panda bears, elephants, zebras, lions, tigers, monkeys and apes), sporting animals (horses and dogs) as well as domesticated animals (dogs and cats). The humans and non-human mammals both be either a male or female.
The sexual disturbances in humans treated by the present invention include hypoactive sexual desire disorder, female sexual arousal disorder, male erectile disorder, female orgasmic disorder and male orgasmic disorder. The sexual disturbances of the present invention are known to those skilled in the art and are adequately described for a medical practitioner. In particular, see Diagnostic and Statistical Manual of Mental
Disorders, Fourth Edition, (DSM-IV), American Psychiatric Association, Washington DC, 1994 as well as the DSM-IV Guidebook, American Psychiatric Press, Inc., Washington DC, 1995.
CC When inducing mating in the non-human mammals it is desirable to treat one member of the mating pair in some cases. This is most likely to be the situation where ] previous attempts at mating the pair have failed and one member of the pair is not known to have prior offspring. In that case, this member would be advantageously treated. In other cases, it may be desirable to treat both the male and female prior to the anticipated mating.
The latter is most likely to be advantageous when the intended mating is between sexually inexperienced animals and prior attempts at mating the pair have failed.
The compounds of formula (A) are also useful in treating humans whose primary disease, condition or situation is not one of sexual disfunction, but rather the primary disease or condition leads to a secondary clinical situation where the human (male or female) experiences diminished sexual desire, interest and/or function. These diseases include epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy and can produce a sexual deficiency state which is treated in the same way as those individuals who have one or more of the five sexual disturbances identified above. The sexually therapeutic effective amount is the same and is administered in the same way by the same routes of administration as for those humans who have sexual disturbances.
The compounds of formula (A) are also useful in increasing sexual desire, interest : or performance in individuals who do not have any of the five sexual disturbances nor any of the following diseases or conditions, epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy. These individuals are treated the same way as those having any of the five sexual disturbances.
The sexually useful effective amount to be used here is the same as the sexually = therapeutically effective amount for those with sexual disturbances. The sexually useful therapeutically effective amount is administered in the same way by the same routes of administration as for those humans who have sexual disturbances.
In (1) treating the sexual disturbances of humans, (2) inducing mating of non-human mammals, (3) treating humans whose primary disease or condition leads to a secondary clinical situation where the human experiences diminished sexual desire, interest and/or function and (4) increasing the sexual desire, interest or performance in individuals who do not have any of the above problems the compounds of formula (A) in the known appropriate pharmaceutical dosage form for a given route of administration may be administered orally, intra-nasally, buccally, intra-pulmonary, parenterally and rectally. For treating humans, it is preferred that the compound of formula (A) be administered orally, intra-nasally, buccally and intra-pulmonarily; it is more preferred that the compounds of 7 formula (A) be administered orally. For treating non-human mammals, it is preferred that the compounds of formula (A) be administered orally, parenterally and rectally; it is more i preferred that the compounds of formula (A) be administered orally.
The operable sexually therapeutic effective amount as well as the operable sexually useful effective amount of the compounds of formula (A) is from about 0.2 thru about 8 mg/person/dose. It is preferred that the sexually therapeutic effective amount and sexually useful effective amount is from about 0.5 thru about 5S mg/person/dose. It is more preferred that the sexually therapeutic effective amount and sexually useful effective amount is from about 1 thru about 3 mg/person/dose. If doses less than this are used the desired effect will not be obtained. If doses greater than this are used, undesirable side effects occur and the desired effect will not be obtained. The term “therapeutic” is used in treating a disease or condition; the term “useful” is used when treating humans who do not have onc of the above diseases or conditions which cause sexual dysfunction but who are considered normal and who wish to increase their sexual desire, interest or performance.
The operable sexually mating amount of the compounds of formula (A) is from about 0.003 thru about 0.2 mg/kg/dose. It is preferred that the sexually mating amount is from about 0.01 thru about 0.125 mg/kg/dose. It is more preferred that the sexually mating
CC amount is from about 0.025 thru about 0.075 mg/kg/dose.
To obtain the desired effect in humans, the sexually therapeutic effective amount or sexually useful effective ambunt of the compounds of formula (A) should be administered from about 10 minutes to about 8 hr prior to sexual activity. It is preferred that the compounds of formula (A) be administered from about 0.5 hr to about 1 hr prior to sexual activity. It is more preferred that the compounds of formula (A) be administered about 0.5 hr prior to sexual activity. Sexual activity includes sexual intercourse with or without orgasm, ejaculation, masturbation and sexual foreplay.
To obtain the desired mating effect in non-human mammals, the compounds of formula (A) is administered from about 10 minutes to about 8 hr prior to mating. It is preferred that the compounds of formula (A) be administered from about 10 minutes to about 1 hr prior to mating. It is more preferred that the compounds of formula (A) be administered from about 10 minutes to about 0.5 hr prior to mating.
It is preferred that the humans do not have Parkinson’s disease.
It is preferred that the in humans administration of the compounds of formuia (A) does not produce postural hypotension.
CC The present invention is further illustrated by EXAMPLES A-P.
The exact dosage of the compounds of formula (A) which are useful in the four ’ methods of this invention depends on the route of administration, the particular compound used, the particular condition being treated, the severity of the condition being treated, the age, weight, general physical condition of the particular patient, other medication the individual may be taking as is well known to those skilled in the art and can be more accurately determined by measuring the blood level or concentration of the compound and/or metabolite in the patient's blood and/or the patient's response to the particular condition being treated.
The compounds of formula (A) can also be used with other agents in (1) treating the five sexual disturbances, (2) in inducing mating of a non-human mammal, (3) in trcating a sexual deficiency state in humans who have one or more of the following diseases/conditions - epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy or (4) increasing sexual desire, interest or performance in a human who does not have any sexual disturbance or one of the above diseases/conditions. It is known that vascular smooth muscle relaxation is necessary for vascular engorgement of the penis and the clitoris during normal male and female sexual behavior and that agents which promote vascular engorgement of the penis and : clitoris are useful in enhancing sexual motivation, desire and performance. Agents which effectuate vascular smooth muscle relaxation include phosphodiesterase type 5 inhibitors, such as sildenafil (Viagra) atid ICOS-351; phosphodiesterase type 3 inhibitors, such as milrinone; non-selective phosphodiesterase inhibitors such as papaverine; nitric oxide donor drugs such as linsidomine; alpha type 1 adrenergic receptor antagonists such as phentolamine produce relaxation of vascular smooth muscle from human penis in the presence of norepinephrine; alpha type 2 adrenergic receptor antagonists such as yohimbine; prostaglandin E1 receptor agonists such as PGE1 (CAVERJECT™ Injection and MUSE™); as well as vasoactive intestinal polypeptide (VIP) agents.
These vascular smooth muscle relaxation agents are administered by oral, parenteral, buccal, rectal, intranasal, intrapulmonary, intraurethral or topical routes. The preferred route of administration will depend on the specific properties of the drug(s) to be combined with the compound(s) of formula (A). The preferred route of administration for a phosphodiesterase type 3 or 5 receptor inhibitor and an alpha type 1 or 2 adrenergic receptor inhibitor is oral. The preferred route of administration for a prostaglandin E receptor : 15 agonist, nitric oxide donor, non-specific phosphodiesterase inhibitor, and VIP is intracavernosal injection or intraurethral topical administration in male mammals or topical © administration to the vulva in the female.
The dose of some of the vascular smooth muscle relaxation agents is known to those . skilled in the art, especially for sildenafil (VIAGRA™ Tablets), PGE1 (CAVERJECT™
Injection and MUSE™). For yohimbine the dose is about 1 to about 10 mg orally and can be given about three or four times daily as a routine. For phentolamine the dose is about 2 to about 40 mg orally or by bucal patch or about 0.5 to about 5 mg when given by intracavernosal injection. For papaverine the dose is about 4 to about 20 mg given by intracavernosal injection. For VIP the dose is about 5 to about 60 mg when given by intracavernosal injection.
When the compounds of formula (A) are used in conjunction with the vascular smooth muscle relaxation agents the compounds of formula (A) should be administered within the time frame discussed above. The sexually effective time period for administration of the vascular smooth muscle relaxation agents is well known for sildenafil (VIAGRA™ Tablets), PGE1 (CAVERJECT™ Injection and MUSE™), The sexually effective time period for administration of yohimbine is about 0 to about 4 hours before sexual activity; for phentolamine it is about 0 to about 4 hours prior to sexual activity when given orally or buccally and about 0 to about 2 hours when given by intracavernosal injection; for papaverine and VIP it is about O to about 2 hours prior to sexual activity.
When used in combination, the preferred combinations are (SR)- (methylamino)-5,6-dihydro-3H-imidazo(4,5,1-ij]Jquinolin-2(1H)-one and sildenafil, (5R)- (methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ijlquinolin-2(1H)-one and PGE]I, (SR)-5- (methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ijjquinoline-2(1H)-thione and sildenafil or (SR)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and PGEI.
DEFINITIONS AND CONVENTIONS
The definitions and explanations below are for the terms as used throughout this entire document including both the specification and the claims.
I. CONVENTIONS FOR FORMULAS AND DEFINITIONS OF VARIABLES
The carbon atom content of variable substituents is indicated in one of two ways.
The first method uses a prefix to the entire name of the variable such as "C,-C,", where both "1" and "4" are integers representing the minimum and maximum number of carbon atoms in the variable. The prefix is separated from the variable by a space. For example, "C;-C, alkyl” represents alkyl of 1 through 4 carbon atoms, (including isomeric forms thereof unless an express indication to the contrary is given). Whenever this single prefix is
CC given, the prefix indicates the entire carbon atom content of the variable being defined.
Thus C,-C, alkoxycarbonyl describes a group CH3-(CH2),-O-CO- where n is zero, one or ’ two. By the second method the carbon atom content of only each portion of the definition is indicated separately by enclosing the "C;-C;" designation in parentheses and placing it immediately (no intervening space) before the portion of the definition being defined. By this optional convention (C,-Cj)alkoxycarbonyl has the same meaning as C,-C4 alkoxy- carbonyl because the "C,-C3" refers only to the carbon atom content of the alkoxy group.
Similarly while both C,-C¢ alkoxyalkyl and (C;-Cs)alkoxy(C,-Cs)alkyl define alkoxyalkyl groups containing from 2 to 6 carbon atoms, the two definitions differ since the former definition allows either the alkoxy or alkyl portion alone to contain 4 or 5 carbon atoms while the latter definition limits either of these groups to 3 carbon atoms.
IL DEFINITIONS
All temperatures are in degrees Centigrade.
TLC refers to thin-layer chromatography.
HPLC refers to high pressure liquid chromatography.
Saline refers to an aqueous saturated sodium chloride solution.
Chromatography (column and flash chromatography) refers to purification/separation of compounds expressed as (support, eluent). It is understood that : the appropriate fractions are pooled and concentrated to give the desired compound(s).
NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (8) dowtifield from tetramethylsilane. )
CMR refers to C-13 magnetic resonance spectroscopy, chemical shifts are reported in ppm (8) downfield from TMS. ~
Pharmaceutically acceptable refers to those properties and/or substances which are acceptable to the patient from a pharmacological/toxicological point of view and to the manufacturing pharmaceutical chemist from a physical/chemical point of view regarding composition, formulation, stability, patient acceptance and bioavailability.
Pharmaceutically acceptable anion salts include salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH3-(CH_,),-COOH where n is 0 thru 4, HOOC-(CH;)y-COOH where n is as defined above. (Z)-2-butenedioate refers to maleate.
When solvent pairs are used, the ratios of solvents used are volume/volume (v/v).
When the solubility of a solid in a solvent is used the ratio of the solid to the solvent is weight/volume (wt/v). ©
Sexual disturbance refers to hypoactive sexual desire disorder, female sexual arousal disorder, male erectile disorder, female orgasmic disorder, and male orgasmic disorder as ) defined in Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, (DSM-
IV), American Psychiatric Association, Washington DC, 1994 as well as the DSM-IV
Guidebook, American Psychiatric Press, Inc., Washington DC, 1995. These definitions of the particular disease states are as they were defined in 1994 and 1995. The five “sexual disturbances” are still defined the same today. In the future, the terms for these sexual disturbances may change, but one skilled in the art will know and realize the disease states themselves are the same.
Sexual activity includes sexual intercourse with or without orgasm, ejaculation, masturbation and sexual foreplay.
Without further elaboration, it is believed that one skilled in the art can, using the preceding description, practice the present invention to its fullest extent. The following detailed examples describe how to prepare the various compounds and/or perform the various processes of the invention and are to be construed as merely illustrative, and not limitations of the preceding disclosure in any way whatsoever. Those skilled in the art will promptly recognize appropriate v-ariations from the procedures both as to reactants and as 10 reaction conditions and techhiquess.
PREPARATION 1 (R)-Naprozxen chloride
R-naproxen (260 g), metiaylene chloride (3.33 kg) and DMF (8.2 ml) are added to 2 reactor. Oxalyl chloride (191.8 g) is slowly added to this mixture. After addition of the oxalyl chloride, the slurry is stirred at 5 to 10° and then slowly warmed to 20-25°. The resulting mixture is concentratead to remove the methylene chloride, branched octane is added to the concentrate and thes mixture is again concentrated. More branched octane is added to the concentrate and thee mixture is cooled to 0° and stirred to crystallize. The crystal slurry is filtered, the crystal cake is washed with octane and dried at 20-25° to obtain the title compound.
The filtrate from the first acrop is concentrated, branched octane is added and the . mixture is cooled and stirred to obtain a second crop of the title compound. The slurry is filtered, the crystal cake is washed with branched octane and dried at 20-25°.
EXAMPLE 1 1-Benzyl-@&H-imidazo[4,5, 1 -ijlquinolin-2(1H)-one (II) ) A mixture of 4H-imidazol[4,5,1-ij]quinolin-2(1H)-one (I, J. Heterocyclic Chem.,19, 837-49 (1982), 1.0g, 5.8mmol) im DMF (10ml) is cooled to 0° and treated with potassium #- ) butoxide in THF (1.98 M, 3.2 ml,. 6.3 mmol) maintaining the rcaction temperature at 0°. . The resulting mixture is stirred at 0° for 10 minutes. Benzyl bromide (0.73 ml, 6.1mmol) is then added while maintaining the reaction temperature at 0°. After 1 hr, the mixture is partitioned with methyl z-buty! ether (MTBE) from water followed by several water washes.
The MTBE phase is concentrated under reduced pressure. The concentrate is cooled to 0°, filtered and washed two times wish 0° MTBE. The product is dried at 50° under reduced pressure with a nitrogen purge to give the title compound, CMR (CDCl;, 100 MHz) L 153.78, 136.44, 128.69, 127.67, 1 27.60, 126.73, 125.86, 122.90, 122.78, 121.28, 116.92, 116.17, 108.36, 44.95 and 42.37.
EXAMPLE 2 (5R’,6R")- 1-benzyl-5-bromo-6-hydroxy-5,6-dihydro-4H- imidazo[4,55,1-ij]quinolin-2(1H)-one (III) 1-Benzyl-4H-imidazo[4,5 . 1-ij]quinolin-2(1H)-one (II, XAMPLE 1, 240 g), acetonitrile (1.086 kg), water (22% ml) and fluoboric acid (48.5%, 13.4 g) are mixed and cooled to 0 to 5°. Dibromantin (1 63.5 g) is slurried into acetonitrile and is added to the reaction mixture. The reaction is carried out for about 3 hr at 0 to 5°. After the reaction is complete, methyl t-butyl ether is added over about 45 minutes keeping the reaction temperature in the pot below 10°. The s-lurry is cooled to -10 to -15°, stirred for an hour and then filtered. The product is washecd with precooled methyl -butyl ether, dried with 40° nitrogen to give the title compound, CMR (CDCl;) 6 156.0, 137.8, 130.5, 129.6, 129.3, 129.1, 126.6, 123.6, 122.5, 119.6, 110.4 , 69.9, 49.6, 47.7, 46.9 and 43.8. - 5s EXAMPLE3 (5S,6S)-1-Benzyl —5-bromo-2-0x0-1,2,5,6-tetrahydro-4H- imidazo[4,5,1-ijlquinolin-6-yl (2R)-2-(6-methoxy-2- naphthyl)propano ate (IVA) and (5R,6R)-1-benzyl-5-bromo-2-oxo- 1,2,5,6-tetrahydrae-4H-imidazo(4,5,1-ij]quinolin-6-yl (2R)-2-(6- methoxy-2-naphtbhyl)propanoate (IVB) (5R,6R)-1-Benzyl-5-bromo-6-hy-droxy-35,6-dihydro-4H-imidazo([4,5, 1-ij]quinolin- 2(1H)-one (III, EXAMPLE 2, 143 g), methylene chloride (3,136 g), N-methyl morpholine (100.2 g) and 4-dimethylaminopyridine «497 mg) are added to the reactor and the mixture is cooled to 0 to 5°. (R)-Naproxen chloride (PREPARATION 1, 118.5 g) dissolved in methylene chloride (694 ml) is added to the reactor over about 1 hr and the mixture is stirred at O to 5° to complete the reactiora. If necessary, additional naproxen chloride is added to complete the reaction. Potassitam carbonate solution diluted with water is added to ~~ the mixture. The aqueous phase is extra_cted with methylene chloride and the combined methylene phase is washed with water. “The washed mixture is concentrated by vacuum ’ distillation and solvent exchange with et hyl acetate is performed. The concentrate is cooled to - 10° and stirred. The crystal slurry is filtered and the crystal cake is washed with precooled methyl r-buty! ether and dried at 50° to give the title compound in solid form, (5S,6S)-1-benzyl-5-bromo-2-0x0-1,2,5,6-tetrahydro-4H-imidazo[4,5,1-ij]quinolin-6-yl (2R)-2-(6-methoxy-2-naphthyl)propanoaate (IVA), CMR (CDCl;) 6 173.2, 157.8, 153.4, 136.1, 134.6, 133.7, 129.2, 128.8, 127.8. 127.8, 127.6, 127.2, 125.9, 125.9, 125.6, 121.5, 121.4,119.1, 113.2, 109.0, 105., 105.6, €9.2, 55.3,45.4,45.2,42.5,41.7 and 18.3.
The undesired isomer, (SR,6R)-1 -benzyl-5-bromo-2-oxo-1,2,5,6-tetrahydro-4H- imidazo{4,5,1-ij]quinolin-6-yl (2R)-2-(6—methoxy-2-naphthyl)propanoate (IVB) is in the filtrate and can be recovered by means w=ell known to those skilled in the art, (SR,6R)-1- benzyl-5-hydroxy-6-(methylamino)-5,6-cdihydro-4H-imidazo[4,5,1-ijlquinolin-2(1H)-one,
CMR 173.2,157.9, 153.4, 136.1, 135.0, 133.8, 129.2, 128.9, 128.8, 127.8, 127.6, 127.4, 125.8, 125.8, 125.7, 121.6, 121.5, 119.3, 113.1, 109.1, 105.7,68.7, 55.3, 45.3, 45.2, 42.2, 41.3 and 18.1 8.
EXAMPLE 4 (5R,6R)-1-benzyl-5-hydroxy-6-(methylamino)-5,6-dihydro-4H- imida%o[4,5,1-ij]quinolin-2(1H)-one (V) (58,6S)-1-Benzyl-5-bromo-2-ox0-1,2,5,6-tetrahydro-4H-imidazo[4,5,1- ijlquinolin-6-yl (2R)-2-(6-methoxy-2-naphthyl)propanoate (IVA, EXAMPLE 3, 110 g) is slurried in acetonitrile (1,297 g). After adding aqueous methylamine (40 wt %, 327 g) the reaction is carried out for about 12 hr at about 30°. After the reaction is complete, the mixture is concentrated and ethyl acetate is added. Dilute hydrochloric acid is added to make the water-soluble salt of the title compound. The byproduct (R-naproxen acetamide impurity) is insoluble in water and stays in the ethyl acetate phase. Further extractions and washes are carried out for better separation of the (naproxen acetamide) impurity with minimum loss of the desired product. Then a sodium hydroxide solution is added to the aqueous phase and the hydrochloride salt of the title compound is converted to the free } base. The free base is less soluble in water and is extracted into ethyl acetate. The product mixture is concentrated and solvent exchanged with ethyl acetate to remove water.
Crystallization is performed by adding branched chain octane and cooling the mixture. The ) resulting slurry is filtered, washed and dried at 50° to give the title compound, CMR (CDCl) 6 153.7, 136.3, 128.7, 127.8, 127.7, 125.7, 121.3, 119.9, 118.6, 107.5, 66.2, 60.1, 45.1, 42.6 and 34.0.
EXAMPLE 5 (7aS,8aR)-4-benzyl-8-methyl-7,7a,8,8a-tetrahydroazireno[2,3- climidazo[4,5,1-ijlquinolin-5(4H)-one (VI) 5R,6R)-1-benzyl-5-hydroxy-6-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ijJquinolin-2(1H)-one (V, EXAMPLE 4, 70 g) and THF (1,389 g) is concentrated to remove any moisture with distillate as a precaution due to reactivity of n-butyl lithium towards water. The mixture is cooled to about -10° and n-butyllithium is added to make the lithium salt of the starting material with formation of n-butane byproduct in an exothermic reaction.
Benzene sulfonyl chloride is added slowly to make benzene sulfonate in an exothermic reaction. The reaction mixture is warmed to 20-25° to complete the reaction. Agueous potassium carbonate solution is added to scavenge the benzene sulfonic acid and the mixture is stirred to allow crystallization. Water is added to complete crystallization, the slurry is stirred, cooled and filtered. The crystal cake is washed with water followed by branched chain octane and dried at 40 to 50° to give the title compound, CMR (CDCls) & 154.1, 136.3, 128.6, 127.9, 127.6, 124.3, 120.7, 119.7, 107.4, 46.7, 44.9, 40.7, 38.1 and 37.6.
EXAMPLE 6 (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin- 2(1HY-one (VIN)
A mixture of (7aS,8aR)-4-benzyl-8-methyl-7,7a,8,8a-tetrahydroazireno[2,3- c)imidazo[4,5,1-ijlquinolin-5(4H)-one (VI, EXAMPLE 5, 40 g) r-amyl alcohol (42.4 g) and anhydrous ammonia (1,200 g) is treated with lithium at -33° . After the lithium addition is complete, the reaction mixture changes from a yellow slurry to a dark blue mixture. This dark blue mixture is stirred for 30-60 minutes and then quenched with the addition of water.
The cooling is removed from the condenser and the ammonia is allowed to evaporate. The residue is dissolved in methanol. This mixture is then concentrated to dryness to give the title compound, which is carried on directly to the next step without isolation.
EXAMPLE 7 (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ij]quinolin- 2(1H)-one (Z)-2-butenedioate (1:1) (VIII) (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijJquinolin-2(1H)-one (VII,
EXAMPLE 6, 28.0 g) is dissolved in water and the pH is adjusted to 10 with the addition of hydrochloric acid. The mixture is applied in portions to an XAD-16 resin column which is eluted first with water and then with ethanol. The inorganic salts are eluted from the * column first with the desired product eluted with the ethanol. The ethanol eluate from the column is treated with maleic acid and the water level is lowered through azeotropic ) distillation of the ethanol. The precipitated product is isolated by filtration, rinsed with ethyl acetate and dried to give the title compound, CMR (DMSO-d) & 167.6, 153.9, 136.4, 127.1, 121.5, 119.6, 114.1, 107.5, 51.9, 31.3 and 26.5.
EXAMPLE 8 (SR)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ijlquinoline- 2(1H)-thione
A mixture of (SR)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (VI, EXAMPLE 6, 15.0 g, 73.8 mmol) and tetraphosphorus decasulfide (36.1 g, 81.2 mmol) in pyridine (300 mL) is heated in a 125° oil bath under nitrogen. The reaction is stirred for 5 hr. The mixture is cooled to 20-25° and the pyridine is removed under reduced pressure. Sodium hydroxide (2.2 N, 200 mL) is added. Sodium hydroxide (1 N) is then added. The mixture is saturated with sodium chloride and extracted with methylene chloride (2.5L, in portions). The organic phase is absorbed onto silica gel (40 g) and purified via column chromatography (silica gel; 225 g; methanol/methylene chloride, 3.5- 5.0/96.5-95) to give a solid. Recrystallization of this material from methanol/ethyl : acetate/hexanes give the title compound, mp = 210-213°; IR (drift) 2940, 2907, 2884,
1483, 1458, 1391, 1366, 1354, 1254, 1239, 1229, 895, 762, 734, 630 cm™; NMR (300
MHz, CDCl,) 7.12, 7.03, 700, 4.30, 3.96, 3.30-3.50, 3.15, 2.88 and 2.57 8; MS (EI, m/z) 219 (MM), 190, 189, 187, 186, 164, 163, 155, 145; HRMS (FAB) calculated for C;,H;3N3S (MH") = 220.0908, found 220.0904. ”
EXAMPLE?Y9 (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline- 2(1H)-thione malate
A mixture of maleic acid (0.317 g, 2.36 mmol) in a minimal amount of methanol (~ 1 mL) is added to a mixture of (SR)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline- 2(1H)-thione (EXAMPLE 8, 0.493 g, 2.25 mmol) in methylene chloride. The resulting solid is collected by filtration to give the title compound, mp = 195-196°; [}®p = -60° (c 0.93, methanol); IR (drift) 3140, 3112, 3060, 2969, 1627, 1619, 1568, 1481, 1455, 1398, 1389, 1361, 1220, 868 and 747 cm™'; NMR (300 MHz, CD;0D) 7.20-7.30, 7.10-7.20, 6.26, 4.49, 4.31, 4.05-4.20, 3.47, 3.28 and 2.83 §; CMR (100 MHz, DMSO-d + CD;0D) 170.4, 169.4, 136.6, 131.1, 130.9, 125.1, 122.1, 116.2, 109.6, 53.9, 43.1, 31.9 and 27.2 §; MS (ESI, m/z) 220.1 (MH).
EXAMPLE A Hypoactive Sexual Desire Disorder In A Female Patient
A 44 kg, 24 year old female patient is referred by her psychologist for evaluation for ) and medical treatment of hypoactive sexual desire disorder. The patient recently began to co-habitate with a 28 year old man. She consulted a clinical psychologist because of distress over frequent arguments with her partner. These arguments concern her frustration that her partner is unwilling to marry her and the partner’s accusations that she is sexually unresponsive and “boring in bed.” The patient reports that although she desires to continue the relationship, she has little or no interest in sexual activity with this partner. The partner initiates all sexual activity in the relationship and she complies so that the relationship will continue. She states that her partner desires sexual intercourse about once per day.
Occasionally, the couple’s frequency of sexual intercourse is as much as twice per day. She reports that she does not have sexual fantasies since the present relationship began. The patient had a previous relationship with a man that lasted 3 years and involved sexual activity that she found sexually exciting and satisfying. The patient has recently had a physical examination by her family physician, the findings of which were unremarkable.
She currently takes no prescription drugs other than low dose birth control pills. She does not routinely use over-the-counter medications or alcohol and denies taking drugs of abuse.
The patient is diagnosed as having Hypoactive Sexual Desire Disorder of acquired onset due to situational factor (Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition, 1994). (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-i Jquinolin-2(1H)-one (Z)-2-butenedioate (1:1) is prescribed at 1 mg/dose to be taken 0.5 hr before the patient } intends to engage in sexual activity. The patient is instructed that she may use the drugona daily basis, if she and her partner desire sexual activity at this frequency. She is also instructed that on occasions she may use the drug twice in a single day if this is the intended frequency of intercourse. The patient is examined after one month. She reports that she uses the drug once, and occasionally twice, per day. She reports that she has sexual fantasies on 3-4 occasions per week, occasionally initiates sexual activity with her partner, and enjoys an improved sexual relationship with her partner. She also reports that she and : her partner argue less frequently and that her partner no longer accuses her of being disinterested in sexual relations. The patient is instructed to continue using the drug.
EXAMPLE B Female Sexual Arousal Disorder In A Female Patient
A 64 kg, 22 year old female patient is complaining of vaginal dryness and mild discomfort during sexual intercourse. The patient recently began a relationship with a 35 ) year old man. Her partner complained of her vaginal dryness and poor vaginal expansion during sexual intercourse. Her partner has made several comments about this during the - previous two months and the patient is concerned that her partner is dissatisfied with her lack of sexual responsiveness and may end the relationship. The patient reports that she : desires to continue the relationship. The patient has had several previous sexual relationships. She reports that vaginal dryness and some discomfort with vaginal intercourse has occurred during her past sexual relationships. On questioning, she indicates that she has little or no sense of sexual arousal during intercourse. The patient indicates that she has sexual fantasies several times per week. She finds her current partner attractive and sexual desirable. She indicates that she masturbates approximately once per week.
During these episodes she usually has an orgasm. Lubrication is not a problem when she masturbates. The patient has recently had a physical examination by her family physician, the findings of which were unremarkable. She currently takes no prescription drugs other than low dose birth control pills. She does not routinely use over-the-counter medications or alcohol and denies taking drugs of abuse. The patient is diagnosed as having Female
Sexual Arousal Disorder that is situational due to psychological factors (Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition, 1994). (5R)-(methylamino)-5,6- dihydro-4H-imidazo(4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1) is prescribed at 3 mg/dose to be taken 0.5-1 hr before the patient intends to engage in sexual activity. The patient is instructed that she may use the drug on a daily basis, if this is the intended a WO 00/40226 PCT/US99/27951 frequency of sexual activity. The patient is examined after one month. She reports that she uses the drug prior to interc8urse. She reports that vaginal dryness is no longer a problem and that she no longer has pain during initiation of vaginal penetration by her partner. She enjoys an improved sexual relationship with her partner. The patient is instructed to continue using the drug.
EXAMPLE C Male Erectile Disorder
A 75 kg, 56 year old male patient has been married for 20 years. He presents complaining that for the past six months he has had difficulty maintaining an erection until completion of sexual intercourse. He develops an adequate erection at the beginning of sexual activity but detumescence occurs when he attempts penetration. His wife is his only current sexual partner. He reports that his wife is patient and understanding of his problem but that he is embarrassed, feels that he is a failure, and is growing progressively more angry and sad about his inability to maintain an erection. He masturbates approximately twice each month. During masturbation, he is usually able to maintain an erection until he ejaculates. The patient has recently had a physical examination by his family physician.
The only remarkable findings were a supine diastolic blood pressure 94 mm mercury and a total plasma cholesterol level of 230 mg/dl. He was instructed to follow the American ) Heart Association dietary recommendations and to reduce his body weight by 5 kg. He currently takes no prescription drugs. He does not routinely use over-the-counter medications or alcohol and denies taking drugs of abuse. The patient is diagnosed as having Male Erectile Disorder that is acquired and situational. The etiology is most likely due to psychological factors, although combined factors, e.g., mild hypertension or atherosclerosis, may contribute (Diagnostic and Statistical Manual of Mental Disorders,
Fourth Edition, 1994). (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) is prescribed at 3 mg/dose to be taken 0.5 hr before the patient intends to engage in sexual activity. The patient is instructed that he may use the drug on a daily basis, if this is the intended frequency of sexual activity. The patient is examined after one month. He reports that he uses the drug prior to intercourse. He reports that he maintains an erection for a satisfactory period after vaginal penetration in almost every attempt at intercourse. He usually experiences intra-vaginal ejaculation. The patient and his wife consider the quality of their sexual relationship to be markedly improved. The patient is instructed to continue using the drug.
EXAMPLE D Female Orgasmic Disorder
A 50 kg, 22 year old female patient who married three months before presenting for treatment. She complains tMat she does not have an orgasm during sexual activity with her ’ husband even though she enjoy the experience and become sexually excited during intercourse. She was not sexually active prior to marriage. She reports that her husband had multiple premarital partners and that he reports all his past partners had orgasms. The patient is upset by her inability to have orgasms and feels she is an poor wife. On questioning she reports that she is “too fat” although her weight is appropriate for her height. She does not masturbate. The patient has recently had a physical examination by her family physician, the findings of which were unremarkable. She currently takes no prescription drugs other than low dose birth control pills. She does not routinely use over- the-counter medications or alcohol and denies taking drugs of abuse. The patient is diagnosed as having Female Orgasmic Disorder that is situational due to psychological factors (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 1994). (5R)-( methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) ) is prescribed at 1 mg/dose to be taken about 0.5 hr before the patient intends to engage in sexual activity: The patient is instructed that she may use the drug on a daily basis, if this is - the intended frequency of sexual activity. The patient is examined after two months. She reports that she uses the drug prior to intercourse. She reports that she has an orgasm - during sexual intercourse on most occasions. She enjoys an improved sexual relationship with her partner. It is recommended that the patient continue to use the drug for an _ additional six months, then stop taking the drug for a period of two weeks to determine whether she might now be able to have orgasms in the absence of drug therapy.
EXAMPLE E Male Orgasmic Disorder
A 80kg, 40 year old man has been married for 15 years. He presents complaining that he has begun to have difficulty achieving an orgasm during vaginal intercourse with his wife. On most occasions he is unable to ejaculate during sexual intercourse. Infrequently, he is able to ejaculate during sexual, but only after very prolonged vaginal intercourse. He indicates that this has been occurring for at least three months and that he is frustrated and angry about the situation. His further reports that his wife finds the prolonged intercourse that he requires to ejaculate uncomfortable and has begun avoiding sexual relations. He reports that he ejaculate normally when he masturbates. The patient has recently had a physical examination by his family physician, the findings of which were unremarkable. He currently takes no prescription drugs. He does not routinely use over-the-counter : medications or alcohol and denies taking drugs of abuse. The patient is diagnosed as having Male Orgasmic Disorder that is acquired and situational due to psychological factors (Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, 1994). (5R)- (methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ij}quinolin-2(1H)- one (Z)-2-butenedioate (1:1) is prescribed at 3 mg/dose to be taken 0.5-1 hr before the patient intends to engage in sexual activity. The patient is instructed that he may use the drug on a daily basis, if this is the intended frequency of sexual activity. The patient is examined after one month. At this visit he reports that he now ejaculates during vaginal intercourse on all occasions. The patient and his wife consider the quality of their sexual relationship to be markedly improved. The patient is instructed to continue using the drug.
EXAMPLEF Mating of Animals of Commercial Value
An adult male Giant Panda on temporary loan from a foreign zoo is desired to have breed to an adult female Giant Panda which is normally resident at the zoo. Because of the commercial value of a potential off-spring it is desirable that the animals mate during the time the adult male is on loan. Both animals are sexually inexperienced and do not engage in intercourse during a two week period. As an alternative to anesthetizing the animals for
C- a facilitated transfer of semen between the animals, the male and female Giant Pandas have (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) : ) added to their diet on one occasion. The concentration of drug in the diet is calculated to deliver 0.05 mg of free base equivalents of (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1) per kilogram of body weight. One hour after ingesting the diet containing drug, the animals engage in sexual intercourse. A pregnancy and subsequent birth of an off-spring results from this intercourse.
EXAMPLE G Reduced Sexual Function In A Male With Idiopathic Epilepsy
A 40 year old, 75 kg male patient has idiopathic epilepsy. He first presented with primary generalized seizures at age 15 years and was diagnosed with idiopathic epilepsy.
He has been treated with carbamazepine since age 20. Currently he receives 500 mg/day of the drug. He has had two tonic-clonic seizures during the preceding year. The patient complains of diminished sexual interest in his wife of 8 years. On those occasions when he attempts sexual intercourse, he is able to maintain an erection sufficient for intercourse one- third of the time. He indicates that this problem has had a gradual onset over the previous 5 years. He reports that he rarely has sexual fantasies and rarely masturbates. The patient has recently had a physical examination by his family physician, the findings of which were unremarkable. He currently takes no prescription drugs other than carbamazepine. He does not routinely use over-the-counter medications or alcohol and denies taking drugs of abuse.
A penile injection test with Caverject™ Injection results in a normal erection and duplex
Doppler ultrasonography indicates an intact vascular system. Plasma testosterone and sex hormone binding globulin assays are performed. The plasma testosterone level is 25 nM, which is considered normal. The plasma sex hormone binding globulin level is 55 nM, which is considered elevated compared to the normal range. The patient is diagnosed with hypogonadism, secondary to chronic carbamazepine treatment (Epilepsia 36: 366-370, 1995). (5R)-(methylamino)-5,6-dihydro4H-imidazo[4,5,1-ijJquinolin-2(1H)-one (Z)-2- butenedioate (1:1) is prescribed at 3 mg/dose to be taken 0.5 hr before the patient intends to engage in sexual activity. The patient is instructed that he may use the drug on a daily basis, if this is the intended frequency of sexual activity. The patient is examined after one month. He reports that he take the drug 2-3 times per week. After taking the drug, he feels more interest in sex and usually initiates sexual activity with his wife. He reports that enjoys a normal sexual relationship. The patient is instructed to continue with the treatment.
EXAMPLEH Reduced Sexual Function In A Male Patient With Erectile
Dysfunction And Hypoactive Sexual Desire Disorder =
A 55 year old, 70 kg, male patient is apparently in good health. He presents complaining of a loss of sexual desire and frequent erectile dysfunction since taking an : executive position in his company, six weeks previously. He reports that he works long hours and feels a high degree of pressure associated with his job. He is frustrated and angry that when he takes time off from work he is unable to have an intimate relationship with his wife. He reports that although he is periodically interested in initiating sexual relations, on most occasions he is unable to maintain a high level of interest sufficiently long to initiate or to adequately respond to his wife’s initiating sexual activity. He further indicates that for the past six months, he has had difficulty maintaining an erection until completion of sexual intercourse. He develops a semi-rigid erection at the beginning of sexual activity but detumescence occurs when he attempts penetration. He reports that he has few erotic fantasies. He has not masturbated for the past several months. He attributes this to a lack of motivation and interest. The patient has recently had a physical examination by his family physician, the findings of which were unremarkable. He does not routinely use over- the-counter medications or alcohol and denies taking drugs of abuse. (5R)-(methylamino)- 5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one (Z)-2-butenedioate (1:1), 3 mg/dose, and sildenafil (VIAGRA Tablets), 50 mg/dose, are both prescribed. Each is to be taken orally about 0.5 hr before the patient intends to engage in sexual activity. The patient is instructed that he may use the drug combination on a daily basis, if this 1s the intended frequency of sexual activity: The patient is examined after one month. He reports that he takes the drug combination 2-3 times per week. After taking the drug combination he feels motivated to initiate sexual activity, readily has sexual fantasies that are sustained during sexual intercourse, and has no difficulty maintaining an erection to completion of sexual intercourse. He reports that he enjoys an improved sexual relationship with his partner.
The patient is advised to continue taking the (SR)-(methylamino)-5,6-dihydro-4H- imidazo[4,5,1-ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) for another six months as he adapts to the situational stress associated with his new job. After this time he is advised to stop taking the drug for a period of two weeks to determine whether his sexual motivation and desire have returned to the level he enjoyed prior to the change in jobs.
EXAMPLE 1 Hypoactive Sexual Desire Disorder In A Female Patient
Following the general method of treatment of EXAMPLE A and making non- : critical variations but using (SR)-5-(methylamino)-5,6-dihydro-4H-imidazo{4,5,1- ijlquinoline-2(1H)-thione in place of (SR)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- - ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained. . EXAMPLE J Female Sexual Arousal Disorder In A Female Patient
Following the general method of treatment of EXAMPLE B and making non-critical variations but using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo{4,5,1-ijlquinoline- 2(1H)-thione in place of (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin~ 2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
EXAMPLE K Male Erectile Disorder
Following the general method of treatment of EXAMPLE C and making non-critical variations but using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline- 2(1H)-thione in place of (SR)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin- 2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
EXAMPLE L Female Orgasmic Disorder
Following the general method of treatment of EXAMPLE D and making non- critical variations but using (SR)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ij]Jquinoline-2(1H)-thione in place of (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
EXAMPLE M Male Orgasmic Disorder
Following the general method of treatment of EXAMPLE E and making non-critical variations but using (5R)-5-Umethylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline- 2(1H)-thione in place of (5SR)~(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin- 2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained. -
EXAMPLEN Mating of Animals of Commercial Value
Following the general method of treatment of EXAMPLE F and making non-critical variations but using (5SR)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quincline- 2(1H)-thione in place of (5R)-(methylamino)-5,6-dihydro-4H-imidazo(4,5, 1-ijlquinolin- 2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
EXAMPLE O Reduced Sexual Function In A Male With Idiopathic Epilepsy
Following the general method of treatment of EXAMPLE G and making non- critical variations but using (SR)-5-(methylamino)-5,6-dihydro-4 H-imidazo[4,5,1- ijlquinoline-2(1H)-thione in place of (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
EXAMPLE P Reduced Sexual Function In A Male Patient With Erectile -
Dysfunction And Hypoactive Sexual Desire Disorder
Following the general method of treatment of EXAMPLE H and making non- - critical variations but using (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo{4,5,1- ijlquinoline-2(1H)-thione in place of (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1- ijlquinolin-2(1H)-one (Z)-2-butenedioate (1:1) the same positive treatment effect is obtained.
CHART A
ES
N 0) .
N—4 / fo)
H
= .
N (in
MN
Ook
OH
H Br
LT am ed
CH, o)
CHART A - continued or fo) O
H Br wv)
N
N
Ol | .
NH-CH,
WOH oo
N (9)
N .
Orel
Pak
N
QC) (Vi)
AN
Oed
CHART A - continued y - (vin
NR
H [0]
NH—CH,4 <0 CH— COOH
N—L ! (Vin) : H™ O CH— COOH
Claims (87)
1. (5R)-5-(Methylamino)-5,6-dihydro-4H-imidazo[4.5, 1-ij]quinoline-2(1H)-thione and pharmaceutically acceptable salts thereof.
2. A compound according to claim 1 which is (5R)-5-(methylamino)-5,6-dihydro-4H- imidazo([4,5,1-ij]quinoline-2(1H)-thione malate.
3. Use of a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4.5, 1-ij]quinolin-2(1H)-one and (5R)-5 -(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2( 1H)- thione and pharmaceutically acceptable salts thereof, for the manufacture of a medicament containing from about 0.5 to about 5 mg of the above compound for use in treating sexual disturbances in a human who is in need of such treatment.
4. Use of a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo{4,5, 1-ij]quinolin-2(1H)-one and (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5 ,1-ij]quinoline-2(1H)- thione and pharmaceutically acceptable salts thereof, for the manufacture of a medicament containing from about 0.5 to about 5 mg of the above compound for use in treating a sexual deficiency state in a human who has epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy and who is in need of such treatment.
5. Use of a compound selected from the group consisting of: (5R)~(methylamino)-S5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2( 1H)-one and (5R)-5-(methylamino)-5 ,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)- thione and pharmaceutically acceptable salts thereof, for the manufacture of a medicament containing from about 0.5 to about 5 mg of the above compound for use in increasing sexual desire, interest or performance in 2 human who is desirous thereof. :
6. Use of a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ijlquinolin-2(1H)-one and -26- AMENDED SHEET
PCT/US99/27951 (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo(4,5, l-ij]quinoline-2(1H)- thione and pharmaceutically acceptable salts thereof, for the manufacture of a medicament for inducing mating a non-human mammal. 5s 7. Use of a compound according to claims 3, 4, 5 and 6 where the compound is (SR)-(methylamino)-5,6-dihydro-4H-imidazo(4,5,1-ij]quinolin-2(| H)-one (Z)-2-butenedioate (1:1).
8. Use of a compound according to claims 3, 4, 5 and 6 where the compound is (5R)- 5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-1 jlquinoline-2(1H)-thione malate.
9. Use of a compound according to claims 3, 4, 5 and 6 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids methanesulfonic, hydrochloric, hydrobromic, sulfuric, phosphoric, nitric, benzoic, citric, tartaric, fumaric, maleic, CH;-(CH,).-COOH where n is 0 thru 4, HOOC- (CH,)n-COOH where n is as defined above.
10. Use of a compound according to claims 3, 4, 5 and 6 where the medicament is used in combination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where both the medicament is administered within 8 hours prior to sexual activity and the vascular smooth muscle relaxation agent is administered within a sexually effective time period prior to sexual activity.
11. Use of a compound according to claim 10 where the vascular smooth muscle relaxation agents is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin El receptor agonists (PGE) and vasoactive intestinal polypeptide (VIP) agents.
12. Use of a compound according to claim 11 where the vascular smooth muscle relaxation agents is selected from the group consisting of sildenafil, ICOS-351, milrinone, papaverine, linsidomine, phentolamine, yohimbine, prostaglandin E1 (PGE1) and VIP. AMENDED SHEET
PCT/US99/27951
13. Use of a compound according to claim 6 where the mammal is a male.
14. Use of a compound according to claim 6 where the mammal is a female.
1S. Use of a compound according to claim 6 where the non-human mammal 1s selected from the group consisting of horses, cattle, swine, sheep, transgenic mice, panda bears, elephants, zebras, lions, tigers, monkeys, apes, dogs and cats.
16. Use of a compound according to claim 15 where the non-human mammal is a male.
17. Use of a compound according to claim 15 where the non-human mammal is a female.
18. Use of a compound according to claims 3, 4 and 5 where the medicament is administered orally, intra-nasally, buccally, intra-pulmonary, parenterally and rectally.
19. Use of a compound according to claim 18 where the medicament is administered orally, intra-nasally, buccally and intra-pulmonary. :
20. Use of a compound according to claim 19 where the medicament is administered orally.
21. Use of a compound according to claim 6 where the medicament is administered orally, parenterally and rectally.
22. Use of a compound according to claim 21 where the medicament is administered orally.
23. Use of a compound according to claims 3, 4 and 5 where the medicament is administered from about 10 minutes to about 8 hr prior to sexual activity. -28- AMENDED SHEET
PCT/US99/27951
24. Use of a compound according to claim 23 where the medicament is administered from about 0.5 hr to about 1 hr prior to sexual activity.
25. Use of a compound according to claim 24 where the medicament is administered about 0.5 hr prior to sexual activity.
26. Use of a compound according to claim 6 where the medicament is administered from about 10 minutes to about 8 hr prior to mating.
27. Use of a compound according to claim 26 where the medicament is administered from about 10 minutes to about 1 hr prior to mating.
28. Use of a compound according to claim 27 where the medicament is administered from about 10 minutes to about 0.5 hr prior to mating.
29. Use of a compound according to claims 3, 4 and 5 where the medicament is administered to a human who does not have Parkinson’s disease.
30. Use of a compound according to claims 3, 4 and 5 where the medicament is administered to a human who does not experience postural hypotension.
31. Use of a compound according to claim 3 where the where the sexual disturbance is selected from the group consisting of hypoactive sexual desire disorder, female sexual arousal disorder, male erectile disorder, female orgasmic disorder, and male orgasmic disorder.
32. Use of a compound according to claim 31 where the sexual disturbance is hypoactive sexual desire disorder.
33. Use of acompound according to claim 31 where the sexual disturbance is female sexual arousal disorder. -29- AMENDED SHEET
PCT/US99/27951
34. Use of a compound according to claim 31 where the sexuzal disturbance is male erectile disorder.
35. Use of a compound according to claim 31 where the sexual disturbance is female orgasmic disorder.
36. Use of a compound according to claim 31 where the sexual disturbance is male orgasmic disorder.
37. Use of a compound according to claims 3, 4 and 5 where tlhe medicament contains from about 1 thru about 3 mg of the compounds.
38. Use of a compound according to claim 4 where the human has epilepsy.
39. Use of a compound according to claim 4 where the human has craniopharyngioma.
40. Use of a compound according to claim 4 where the human. has hypogonadism.
41. Use of a compound according to claim 4 where the human_ has had a hysterectomyoophorectomy.
42. Use of a compound according to claim 4 where the human. has had a hysterectomy.
43. Use of a compound according to claim 4 where the humana has a oophorectomy.
44. Use of a compound according to claim 6 where the mediczament-delivers from about 0.003 thru about 0.2 mg/kg/dose.
45. Use of a compound according to claim 44 where the medicament delivers from about 0.01 thru about 0.125 mg/kg/dose. -30- ~ AMENDED SHEET :
PCT/US99/27951
46. Use of a compound according to claim 45 where the medicament delivers from about
0.025 thru about 0.075 mg/kg/dose.
47. A substance or composition for use in a method of treating sexual disturbances in a human, said substance or composition comprising a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-one, (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ij]quinoline-2(1H)-thione, and pharmaceutically acceptable salts thereof, and said method comprising administering said substance or composition as a medicament containing from about 0.5 to about 5 mg of the above compound.
48. A substance or composition for use in a method of treating a sexual deficiency state in a human who has epilepsy, craniopharyngioma, hypogonadism or who has had a hysterectomyoophorectomy, hysterectomy or oophorectomy, said substance or composition comprising a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one, (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ijlquinoline-2(1H)-thione, and pharmaceutically acceptable salts thereof, and said method comprising administering said substance or composition as a medicament containing from about 0.5 to about 5 mg of the above compound.
49. A substance or composition for use in a method of increasing sexual desire, interest or performance in a human, said substance or composition comprising a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5, 1-ij]quinolin-2(1H)-one, (5R)-5-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione, and pharmaceutically acceptable salts thereof, and said method comprising administering said substance or composition as a medicament containing from about 0.5 to about 5 mg of the AMENDED SHEET
PCT/US99/27951 above compound.
50. A substance or composition for use in a mesthod of inducing mating in a non-human animal, said substance or composition comprisi ng a compound selected from the group consisting of: (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4, §,1-ij]quinolin-2(1H)-one, (5R)-5-(methylamino)-5,6-dihydro-4H-imidaz o[4,5,1-ij]quinoline-2(1H)-thione, and pharmaceutically acceptable salts thereof, and said method comprising administering said substance or composition as a medicament.
51. A substance or composition for use in a metheod of treatment according to claims 47, 48, 49 and 50 where the compound is (5R)-(me thylamino)-5,6-dihydro-4H-imidazo[4,5,1- ijJquinolin-2(1H)-one (Z)-2-butenedioate (1:1).
52. A substance or composition for use in a metheod of treatment according to claims 47, 48, 49 and 50 wherc the compound is (SR)-5-(me-thylamino)-5,6-dihydro-4H-imidazo(4,5,1- ij]quinolin-2(1H)-thione malate.
53. A substance or composition for use in a metheod of treatment according to claims 47, 48, 49 and 50 where the pharmaceutically acceptable salt is selected from the group consisting of salts of the following acids methanesulformic, hydrochloric, hydrobromic, sulturic, phosphoric, nitric, benzoic, citric, tartaric, fuma_ ric, maleic, CH,-(CH,),-COOH where n is 0 thru 4, HOOC-(CH,),-COOH where n is as defined above.
54. A substance or composition for use in a meth«od of treatment according to claims 47, 48, 49 and SO where the medicament is used in combsination with a sexually effective amount of one or more vascular smooth muscle relaxation agents where both the medicament is administered within 8 hours prior to sexual activity and the vascular smooth muscle relaxation agent is administered within a sexually effective time period prior to sexual AMENDED SHEET
PCT/US99/27951 activity.
55. A substance or composition for use in a method of treatment according to claim 54 where the vascular smooth muscle relaxation agents is selected from the group consisting of phosphodiesterase type 5 inhibitors, phosphodiesterase type 3 inhibitors, non-selective phosphodiesterase inhibitors, nitric oxide donor drugs, alpha type 1 adrenergic receptor antagonists, alpha type 2 adrenergic receptor antagonists, prostaglandin E1 receptor agonists (PGE) and vasoactive intestinal polypeptide (VIP) agents.
56. A substance or composition for use in a method of treatment according to claim 55 where the vascular smooth muscle relaxation agents is selected from the group consisting of sildenafil, ICOS-351, milrinone, papaverine, linsidomine, phetolamine, yohimbine, prostaglandin E1 (PGEI) and VIP.
57. A substance or composition for use in a method of treatment according to claims 47, 48 and 49 where thc mammal is a male.
58. A substance or composition for use in a method of treatment according to claim 47, 48 and 49 where the mammal is a female.
59. A substance or composition for use in a method of treatment according to claim 50 where the non-human mammal is selected from the group consisting of horses, cattle, swine, sheep, transgenic mice, panda bears, elephants, zebras, lions, tigers, monkeys, apes, dogs and cats.
60. A substance or composition for use in a method of treatment according to claim 59 where the non-human mammal is a male.
61. A substance or composition for use in a method of treatment according to claim 59 AMENDED SHEET
PCT/US99/27951 where the non-human mmammal is a female.
62. A substance or cormposition for use in a method of treatment according to claims 47, 48 and 49 where the medic-ament is administered orally, intra-nasally, buccally, intra-pulmonary, parenterally and rectallly.
63. A substance or coomposition for use in a method of treatment according to claim 62 where the medicament is administered orally, intra-nasally, buccally and intra-pulmonary.
64. A substance or cosmposition for use in a method of treatment according to claim 63 where the medicament is administered orally.
65. A substance or composition for use in a method of treatment according to claim 50 where the medicament is administered orally, parenterally and rectally.
66. A substance or ccomposition for use in a method of treatment according to claim 65 where the medicament is administered orally.
67. A substance or cormposition for use in a method of treatment according to claims 47, 48 and 49 where the medicament is administered from about 10 minutes to about 8 hr prior to sexual activity.
68. A substance or composition for use in a method of treatment according to claim 67 where the medicament is administered from about 0.5 hr to about 1 hr prior to sexual activity.
69. A substance or composition for use in a method of treatment according to claim 68 where the medicament is administered about 0.5 hr prior to sexual activity. AMENDED SHEET
PCT/US99/27951
70. A substance or composition for use in a method of treatment according to claim 50 where the medicament is administered from about 10 minutes to about 8 hr prior to mating.
71. A substance or composition for use in a method of treatment according to claim 70 where the medicament is administered from about 10 minutes to about 1 hr prior to mating.
72. A substance or composition for use in a method of treatment according to claim 71 where the medicament is administered from about 10 minutes to about 0.5 hr prior to mating.
73. A substance or composition for use in a method of treatment according to claims 47, 48 and 49 where the medicament is administered to a human who does not have Parkinson’s disease.
74. A substance or composition for use in a method of treatment according to claims 47, 48 and 49 where the medicament is administered to a human who does not experience postural hypotension.
75. A substance or composition for use in a method of treatment according to claim 47 where the sexual disturbance is selected from the group consisting of hypoactive sexual disorder, female sexual disorder, male erectile disorder, female orgasmic disorder, and male orgasmic disorder.
76. A substance or composition for use in a method of treatment according to claim 75 where the sexual disturbance is hypoactive sexual desire disorder.
77. A substance or composition for use in a method of treatment according to claim 75 where the sexual disturbance is female sexual arousal disorder.
78. A substance or composition for use in a method of treatment according to claim 75 AMENDED SHEET
PCT/US99/27951 where the sexual disturbance is m.ale erectile disorder.
79. A substance or composition #or use in a method of treatment according to claim 75 where the sexual disturbance is female orgasmic disorder.
80. A substance or composition &or use in a method of treatment according to claim 75 where the sexual disturbance is m ale orgasmic disorder.
81. A substance or composition fosr use in a method of treatment according to claims 47, 48 and 49 where the medicament comtains from about 1 thru about 3 mg of the compounds.
82. A substance or composition for use in a method of treatment according to claim 48 where the human has epilepsy.
83. A substance or composition for use in a method of treatment according to claim 43 where the human has craniopharymgioma.
84. A substance or composition for use in a method of treatment according to claim 48 where the human has hypogonadism.
85. A substance or composition for use in a method of treatment according to claim 48 where the human has had a hyster-ectomyoophorectomy.
86. A substance or composition for use in a method of treatment according to claim 48 where the human has had a hyster-ectomy.
87. A substance or composition for use in a method of treatment according to claim 48 where the human has a oophorecteomy. AMENDED SHEET
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11484099P | 1999-01-06 | 1999-01-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200104283B true ZA200104283B (en) | 2002-05-24 |
Family
ID=22357709
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200104283A ZA200104283B (en) | 1999-01-06 | 2001-05-24 | Method of treating sexual disturbances. |
Country Status (1)
Country | Link |
---|---|
ZA (1) | ZA200104283B (en) |
-
2001
- 2001-05-24 ZA ZA200104283A patent/ZA200104283B/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6921771B2 (en) | Method of treating sexual disturbances | |
JP5989993B2 (en) | Organic compounds | |
US20090239881A1 (en) | Combinations of Flibanserin with Caffeine, Process for Their Preparation and Use Thereof as Medicaments | |
US6555548B2 (en) | Compounds for treating fibromyalgia and chronic fatigue syndrome | |
PT1149579E (en) | Use of an estrogen agonist/antagonist for treating female sexual dysfunction | |
WO2009061681A2 (en) | Antagonists of pgd2 receptors | |
JP2017518355A (en) | Organic compounds | |
US9849133B2 (en) | Pharmaceutical formulations of xanthine or xanthine derivatives, and their use | |
US11571411B2 (en) | Use of a bisamide derivative of malonic acid for treating allergic and other diseases in humans and animals | |
ZA200104283B (en) | Method of treating sexual disturbances. | |
US20060040929A1 (en) | (5R)-(methylamino)-5,6-dihydro-4H-imidazo[4,5,1-ij]quinoline-2(1H)-thione and method of preparation thereof | |
US7041677B2 (en) | Use of monochloroflosequinan in the treatment of sexual dysfunction | |
MXPA01006909A (en) | Method of treating sexual disturbances | |
EP1569649A2 (en) | Use of heterocyclic amine-type compounds as neuroprotective agents | |
ZA200208273B (en) | Compounds for treating fibromyalgia and chronic fatigue syndrome. |